Envestnet Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Envestnet Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,758	Closed	-$1.24M	–	4239
2023 Q3	$1.24M	Sell	10,758 -444	-4%	-$47.7K	﹤0.01%	2652
2023 Q2	$1.15M	Sell	11,202 -55,971	-83%	-$5.91M	﹤0.01%	2645
2023 Q1	$7.33M	Sell	67,173 -184,192	-73%	-$20.4M	﹤0.01%	1422
2022 Q4	$28.6M	Buy	251,365 +9,985	+4%	+$829K	0.01%	678
2022 Q3	$14.9M	Sell	241,380 -48,097	-17%	-$3.36M	0.01%	929
2022 Q2	$23.1M	Buy	289,477 +17,612	+6%	+$1.67M	0.01%	715
2022 Q1	$28.6M	Buy	271,865 +1,229	+0.5%	+$120K	0.01%	688
2021 Q4	$29.2M	Buy	270,636 +24,472	+10%	+$2.67M	0.01%	680
2021 Q3	$27M	Buy	246,164 +15,269	+7%	+$1.59M	0.01%	674
2021 Q2	$21.6M	Buy	230,895 +2,855	+1%	+$263K	0.01%	753
2021 Q1	$21M	Buy	228,040 +74,941	+49%	+$6.32M	0.01%	696
2020 Q4	$11.2M	Buy	153,099 +31,445	+26%	+$2.34M	0.01%	854
2020 Q3	$9.45M	Sell	121,654 -15,193	-11%	-$1.05M	0.01%	838
2020 Q2	$7.61M	Buy	136,847 +39,225	+40%	+$1.68M	0.01%	907
2020 Q1	$2.89M	Sell	97,622 -7,140	-7%	-$242K	﹤0.01%	1248
2019 Q4	$3.79M	Buy	104,762 +23,152	+28%	+$710K	﹤0.01%	1284
2019 Q3	$2.22M	Sell	81,610 -2,043	-2%	-$52.8K	﹤0.01%	1493
2019 Q2	$2.01M	Buy	83,653 +3,634	+5%	+$92.2K	﹤0.01%	1552
2019 Q1	$2.12M	Buy	80,019 +5,812	+8%	+$138K	﹤0.01%	1441
2018 Q4	$1.45M	Buy	+74,207	New	+$1.45M	﹤0.01%	1516
2018 Q3	–	Sell	-4,779	Closed	-$79K	–	3043
2018 Q2	$79K	Buy	4,779 +4,390	+1,129%	+$66.9K	﹤0.01%	2050
2018 Q1	$6K	Sell	389 -2,024	-84%	-$29.9K	﹤0.01%	2593
2017 Q4	$35K	Sell	2,413 -273	-10%	-$3.83K	﹤0.01%	2417
2017 Q3	$34K	Sell	2,686 -35,571	-93%	-$452K	﹤0.01%	2384
2017 Q2	$455K	Sell	38,257 -103,498	-73%	-$1.29M	﹤0.01%	1530
2017 Q1	$2.09M	Buy	141,755 +21,041	+17%	+$341K	0.01%	918
2016 Q4	$1.95M	Buy	120,714 +800	+0.7%	+$14.5K	0.01%	927
2016 Q3	$2.17M	Sell	119,914 -415	-0.3%	-$8.11K	0.01%	923
2016 Q2	$1.98M	Sell	120,329 -3,608	-3%	-$58.4K	0.01%	1041
2016 Q1	$2.05M	Buy	123,937 +104,030	+523%	+$1.82M	0.01%	975
2015 Q4	$431K	Buy	19,907 +2,724	+16%	+$53K	﹤0.01%	1671
2015 Q3	$341K	Buy	17,183 +5,567	+48%	+$176K	﹤0.01%	1764
2015 Q2	$404K	Buy	+11,616	New	+$354K	﹤0.01%	1823

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Envestnet Asset Management's HZNP Position: Q4 2023 in Review

Envestnet Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 10,758 shares — an estimated $1.24M sold.

Envestnet Asset Management first reported a position in HZNP in Q2 2015 and held it in 33 quarters. The position peaked at $29.2M in Q4 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Envestnet Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Envestnet Asset Management sold 10,758 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.24M.
Envestnet Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 33 quarters.
Envestnet Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $29.2M in Q4 2021.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Envestnet Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.